SG Americas Securities
BIB icon

SG Americas Securities’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

SG Americas Securities’s Portfolio BIB Stock Details BIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-8,200
Closed -$650K – 2605
2015
Q1 		$650K Buy
+8,200
New +$608K ﹤0.01% 1333

Other funds holding BIB

AP
Advisors Preferred Rockville, Maryland $679M AUM 22.19% 1-Year Est. Return
VCAM
Valentine Capital Asset Management Danville, California $89.6M AUM 0.84% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
OPPM
Opus Point Partners Management New York $55.3M AUM 7.48% 1-Year Est. Return
PCM
Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BFC
Blue Fin Capital Warren, Rhode Island $610M AUM 26.46% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

SG Americas Securities's BIB Position: Q2 2015 in Review

SG Americas Securities sold out of ProShares Ultra NASDAQ Biotechnology (BIB) in Q2 2015, closing a stake of 8,200 shares — an estimated $650K sold.

SG Americas Securities first reported a position in BIB in Q1 2015 and held it in 1 quarter. The position peaked at $650K in Q1 2015. 27 funds tracked by Wall St. Rank hold BIB as of Q2 2015.

  • SG Americas Securities reported no remaining ProShares Ultra NASDAQ Biotechnology position as of Q2 2015 after selling out during the quarter.
  • SG Americas Securities sold 8,200 ProShares Ultra NASDAQ Biotechnology shares in Q2 2015, an estimated $650K.
  • SG Americas Securities first reported a position in ProShares Ultra NASDAQ Biotechnology in Q1 2015 and held it in 1 quarter.
  • SG Americas Securities's ProShares Ultra NASDAQ Biotechnology position peaked at $650K in Q1 2015.
  • 27 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q2 2015.

Based on SG Americas Securities's 13F filing for Q2 2015, filed 6 Aug 2015.